Abstracts tagged "Disparities"

Abstract Number: PP02 • ACR Convergence 2025
When The Body Speaks But No One Listens: A Dermatomyositis Story Through a Public Health Lens
Kyanna Johnson, Lynn Wilson, Manuel Lubinus, Elisa Glass
Background/Purpose: My journey with dermatomyositis (DM) began abruptly in July 2024, when I was hit by sudden, severe muscle weakness after a GI infection. I…
Abstract Number: 1709 • ACR Convergence 2025
Association Between Social Risk Factors and Major Adverse Cardiovascular Events Among Individuals with Rheumatic Conditions
Leah Santacroce¹, Jeong Yee², Jing Cui³, Emily Oakes¹, Hongshu Guan⁴ and Karen H. Costenbader⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Sungkyunkwan University, Suwon, MA, South Korea, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Individuals with rheumatic conditions are at an increased risk of experiencing cardiovascular events. Social risk factors contribute to disparities in comorbidities and adverse outcomes…
Abstract Number: 1079 • ACR Convergence 2025
Sociodemographic, Clinical, and Community-Level Deprivation Factors are Associated with Health-Related Quality of Life in Systemic Sclerosis
Sarah Smith¹, Paula Ramos², Dulaney Wilson³, Diane Kamen⁴ and Richard Silver¹, ¹Medical University of South Carolina, Charleston, SC, ²Emory University School of Medicine, Atlanta, GA, ³Medical University of South Carolina, Charleston, ⁴Medical University of South Carolina, Johns Island, SC
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease with heterogeneous manifestations and significant impairment in health-related quality of life (HRQoL). SSc outcomes are shaped…
Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…
Abstract Number: 2629 • ACR Convergence 2025
Predictors of 30-day Readmissions in Pregnant Patients with Systemic Lupus Erythematosus: The Impact of Social Determinants of Health.
Sandhya Kannayiram¹, Yiyuan Wu², Lisa Sammaritano³, Michael Lockshin⁴, Rich Caruana⁵, Ware Branch⁶, Jane Salmon³ and Bella Mehta⁷, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Microsoft, Redmond, WA, ⁶University of Utah Health Sciences Center, Salt Lake City, UT, ⁷Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Social Determinants of Health (SDOH) are increasingly recognized as significant contributors to adverse outcomes in pregnant patients with SLE. This study aims to evaluate…
Abstract Number: 1707 • ACR Convergence 2025
Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Soziema Salia¹, Boniface Mensah², Ufuoma Mamoh¹, Gilava Hedayati¹, Terrylyna Baffoe-Bonnie³, Joan Morny⁴ and Christhopher Haas³, ¹MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, ²MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, CA, ³MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, ⁴Piedmont Athens Regional Internal Medicine Residency Program, Athens, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of end-stage kidney disease (ESKD) in young women, particularly among racial and ethnic minorities. Kidney transplantation…
Abstract Number: 1077 • ACR Convergence 2025
Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort
Mrinalini Dey¹, Sam Norton², Andrew Cope², MAYA BUCH³, Richard Osborne⁴, James Galloway² and Elena Nikiphorou², ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²King's College London, London, United Kingdom, ³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ⁴La Trobe University, Melbourne, Victoria, Australia
Background/Purpose: Work status and employment can be impacted in people with inflammatory arthritis (IA). We aimed to assess the association between health literacy and work…
Abstract Number: 0381 • ACR Convergence 2025
Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies
Safoah Agyemang¹, Melicent Miller¹, Tori Justin², Lydia Oberholtzer² and Joy Buie¹, ¹Lupus Foundation of America, Washington, DC, ²Sharp Insight LLC, Montgomery County, MD
Background/Purpose: The purpose of Research Accelerated by You (RAY) is to amplify awareness about clinical research and trials and ensure lupus patient partnership in therapeutic…
Abstract Number: 2615 • ACR Convergence 2025
The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection
Manush Sondhi¹, Bhavik Bansal², Hemant Khandelia¹, Jiha Lee³, Sebastian E Sattui⁴, Siddharth Singh⁵ and Namrata Singh⁶, ¹University of Washington, Seattle, WA, ²UT Southwestern Medical Center, Dallas, ³University of Michigan, Ann Arbor, MI, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵University of California San Diego, San Diego, CA, ⁶University of Washington, Bellevue, WA
Background/Purpose: Financial toxicity (FT) is the financial burden of accessing health care, well known in cancer and increasingly seen in rheumatic disease (RD). We compared…
Abstract Number: 1704 • ACR Convergence 2025
Relationships between Neighborhood Disadvantage, Cumulative Social Disadvantage, and JIA Outcomes: A CARRA Registry Study
William Soulsby¹, John Boscardin², Daniel Horton³, Andrea Knight⁴, Karine Toupin-April⁵ and Emily von Scheven², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Social determinants of health (SDOH) operate across individual, family, and community levels. We previously demonstrated that cumulative social disadvantage, comprised of individual and family-level…
Abstract Number: 1076 • ACR Convergence 2025
Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Arthur Lau⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Although achieving target serum urate (SU) and reducing cardiovascular events are cornerstones of gout management, little is known about contemporary treatment patterns across racial…
Abstract Number: 0368 • ACR Convergence 2025
Factors Associated with Patient Acceptability of Rheumatology Care Delivered by Telemedicine
Hareem Farooq¹, Lesley Jackson¹, Rahima Begum², Gary Cutter², Kenneth Saag³, Jinoos Yazdany⁴ and Maria I. ("Maio") Danila⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴UCSF, San Francisco, CA, ⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Home-based telemedicine is an efficient healthcare delivery approach. A recent randomized clinical trial (RCT) found that in-person visits may be preferred among rheumatology patients.…
Abstract Number: 2565 • ACR Convergence 2025
Assessing Participation in the Lupus Sister Circle Support Group
Khadija Dantata, Wendy Rodgers and Lety Ocana, The Lupus Foundation of America, Washington, DC
Background/Purpose: Relative to White people with lupus (PWL), Black/African American (B/AA) PWL are three times as likely to develop lupus and suffer a severe form…
Abstract Number: 1689 • ACR Convergence 2025
Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
Kimberly Cabrera¹, Priscilla Calvache², Lillian Mendez³, Giselle Morales⁴ and Jillian Rose-Smith², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Patient Advocate, Carteret, NJ, ⁴Hospital for Special Surgery, Glendale, NY
Background/Purpose: SLE is a life-threatening autoimmune disease that disproportionately affects African American (AA), Hispanic/Latino, & Asian populations. These communities experience serious health disparities, including more…
Abstract Number: 1075 • ACR Convergence 2025
Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Fabian Rodriguez Quinonez⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Einstein Medical Center Philadelphia, Philadelphia, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Giant-cell arteritis (GCA) is usually described in people of Northern-European ancestry, and little is known about outcomes in Black and Hispanic (B-His) patients. Using…

1
2
3
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].